This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Life Sciences

In the past several years, China's domestic pharmaceutical consumption has increased dramatically. Pharmaceutical industry sales revenue has grown an average of 21.4 percent annually.  Driven by strong economic growth, increasing urbanization and the health demands of an aging population, China's pharmaceutical market is projected to become one of the world’s largest. By 2020, China is expected to grow its pharmaceutical market volume to $220 billion USD, becoming the second-largest market after the United States.

Deloitte China Life Sciences practice

As a member of the Deloitte Global Life Sciences Industry network, Deloitte China Life Sciences Industry practice works closely with our global counterparts to provide industry players in pharmaceuticals, biotechnology, medical devices, pharmaceutical distribution and CRO with full and feasible solutions with new thinking leveraging our global industry's best practices as well as our knowledge and rich experience in the local market.

Featured highlight

  • Health care reform and life sciences: Threat, opportunity or both?
    Exploring how nearly 300 senior life science executives are meeting the challenges and opportunities of global health care reforms, and the national differences through case studies of China, Brazil and Germany.
  • China life sciences and health care market
    Opportunities, challenges and implications for the life sciences and health care industry in China
  • Know your risks
    Emerging markets, third party intermediaries, and life sciences industry
  • The next phase: Opportunities in China's pharmaceuticals market
    This report focuses in particular on pharmaceuticals companies, both domestic and foreign, and their activities in the China market—all from the viewpoint of prospective investors.

Featured contents

  • ExternalURL
    Social networks for life sciences
    Online social networks are everywhere and life sciences is no exception
  • ExternalURL
    Breaking down the wall
    Integrating clinical development with commercial operations
  • ExternalURL
    R&D leadership development in today’s environment
    Understanding the business of science
  • ExternalURL
    Services thinking for life sciences
    A strategic approach to clinical trial start ups
  • ExternalURL
    Measuring the return from innovation
    Analysis into value measurement at the ""whole R&D business"" level using Internal Rate of Return (IRR).
  • ExternalURL
    Winning in Life Sciences
    Deloitte’s key propositions to the Life Science and Healthcare industries many and varied challenges.
  • ExternalURL
    Critical Priorities for the CIO
    Deloitte has identified 10 priority areas for the CIO spanning IT effectiveness, IT efficiency and IT Capabilities

Related links

  • ExternalURL
    Deloitte global life sciences
    Global reach that you can count on
  • ExternalURL
    Deloitte China services
    Our full range of services
© 2013 Deloitte Touche Tohmatsu in Hong Kong, Deloitte Touche Tohmatsu in Macau, and Deloitte Touche Tohmatsu Certified Public Accountants LLP in the Chinese Mainland. All rights reserved.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/cn/en/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.
Share your comments

 

About this site

Stay connected